

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TAKEDA PHARMACEUTICAL COMPANY LIMITED	11/29/2010

RECEIVING PARTY DATA

Name:	CANBAS CO., LTD.
Street Address:	2-2-1 Otemachi, Numazu City
City:	Shizuoka
State/Country:	JAPAN
Postal Code:	410-0801

PROPERTY NUMBERS Total: 16

Property Type	Number
Application Number:	60350208
Application Number:	10347145
Application Number:	11221348
Application Number:	12328632
PCT Number:	IB0300425
Application Number:	60461109
Application Number:	10819375
PCT Number:	IB0401523
Application Number:	60482750
Application Number:	10877961
Application Number:	12347683
PCT Number:	IB0402591
Application Number:	61053190
Application Number:	61116849
Application Number:	12465536

CH \$640.00 60350208

PCT Number:

JP0959238

CORRESPONDENCE DATA

Fax Number: (703)770-7901

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 703-770-7900

Email: patricia.munoz@pillsburylaw.com, sdipdocket@pillsburylaw.com

Correspondent Name: PILLSBURY WINTHROP SHAW PITTMAN LLP

Address Line 1: 1650 Tysons Boulevard

Address Line 2: P.O. Box 10500

Address Line 4: McLean, VIRGINIA 22102

ATTORNEY DOCKET NUMBER:

087533-000001

NAME OF SUBMITTER:

Donna O. Perdue

Total Attachments: 13

source=CanBas Worldwide Executed Assignment#page1.tif
source=CanBas Worldwide Executed Assignment#page2.tif
source=CanBas Worldwide Executed Assignment#page3.tif
source=CanBas Worldwide Executed Assignment#page4.tif
source=CanBas Worldwide Executed Assignment#page5.tif
source=CanBas Worldwide Executed Assignment#page6.tif
source=CanBas Worldwide Executed Assignment#page7.tif
source=CanBas Worldwide Executed Assignment#page8.tif
source=CanBas Worldwide Executed Assignment#page9.tif
source=CanBas Worldwide Executed Assignment#page10.tif
source=CanBas Worldwide Executed Assignment#page11.tif
source=CanBas Worldwide Executed Assignment#page12.tif
source=CanBas Worldwide Executed Assignment#page13.tif

ASSIGNMENT

THIS ASSIGNMENT ("Assignment") shall be effective as of June 15, 2010 ("the Effective Date").

WHEREAS, **Takeda Pharmaceutical Company Limited**, a Japanese company located at 1-1 Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 JAPAN (the "ASSIGNOR"), effectuates a transfer of its entire right title and interest in certain patents and patent applications to **CanBas Co., Ltd.**, a Japanese company located 2-2-1 Otemachi, Numazu City, Shizuoka 410-0801 JAPAN (the "ASSIGNEE") whereby, *inter alia*, the ASSIGNOR has assigned to the ASSIGNEE its entire right title and interest in certain patents and patent applications as more fully described herein.

NOW, THEREFORE, in consideration of the sum of Ten US Dollars (US\$10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the ASSIGNOR, the ASSIGNOR does hereby confirm the assignment, transfer, conveyance, delivery, and grant unto the ASSIGNEE, effective as of the Effective Date, of all of its right, title, and interest in and to the patents and patent applications listed in the attached **Exhibit A**, and all patents and/or applications claiming priority to said patents or patent applications or having priority claims in common with said patents or patent applications, all divisions, continuations, reissues, continuations-in-part (CIP), continued prosecution applications (CPA), requests for continued examination (RCE), substitutes, renewals, reinstatements, and extensions thereof, the inventions described or claimed in said patents or patent applications, and the right to claim priority based on the filing date of said patent applications and based on the filing date of any provisional applications of which said patent applications claim the benefit under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other laws and treaties of like purposes, including the right to sue and recover for all past, present and future infringement of any of said patents or patent applications which subsequently issue as patents, or are reissued or extended, as fully and entirely as the same would have been held and enjoyed by the ASSIGNOR had the assignment, sale, and transfer not been made (collectively, "Assigned Patent Rights");

AND the ASSIGNOR authorizes the ASSIGNEE to apply in all countries and patent offices for patents and like rights of exclusion and for inventor's certificates for said inventions that claim priority to the patents or patent applications of the Assigned Patent Rights; and the ASSIGNOR so agrees for itself and its legal representatives and assigns, without further compensation;

AND the ASSIGNOR hereby authorizes and requests the United States Commissioner of Patents and Trademarks, or any other proper officer or agency of any country, to issue all Letters Patent to the ASSIGNEE, as assignee of the entire right, title and interest, for any and all patents which may be issued and granted on or as a result of the patent applications of the Assigned Patent Rights, in accordance with the terms of this Assignment;

AND the ASSIGNOR agrees that, upon ASSIGNEE's request, the ASSIGNOR will perform such lawful acts and execute such further assignments, applications, statements, and other lawful documents as the ASSIGNEE may reasonably request to effectuate fully this Assignment;



AND the terms, covenants and provisions of this Assignment shall inure to the benefit of the ASSIGNEE, its successors, assigns, and other legal representatives, and shall be binding upon the ASSIGNOR, its successors, assigns and legal representatives.

IN WITNESS whereof that parties hereto have executed this Assignment as of the Effective Date:

Signature: Yoichi Okumura Date: November 29, 2010

Signed for and on behalf of **Takeda Pharmaceutical Company Limited**

Signature of: **Yoichi Okumura**

Title: **General Manager, Intellectual Property Dept.**

NOTARIAL ACKNOWLEDGMENT

STATE OF OSAKA

COUNTRY OF JAPAN


On _____ 2010, before me, the undersigned, a Notary Public in and for said State, personally appeared YOICHI OKUMURA, personally known to me or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Sign _____

Signature of Notary Public


Official seal:





ACKNOWLEDGEMENT OF ASSIGNMENT

I **Takumi Kawabe**, an authorized signatory of **CanBas Co., Ltd.** (the ASSIGNEE), a having a place of business at 2-2-1 Otemachi, Numazu City, Shizuoka 410-0801 JAPAN, acknowledge and accept the above assignment executed by **Takeda Pharmaceutical Company Limited** (the ASSIGNOR) and the transfer of all rights, title, and interest in the inventions in the Assigned Patent Rights as confirmed in said Assignment.

Signature:  Date: Nov 5, 2010

Signed for and behalf of **CanBas Co., Ltd.**

Signature of: **Takumi Kawabe**

Title: **President and CEO, CanBas Co., Ltd.**

NOTARIAL ACKNOWLEDGMENT

STATE OF SHIZUOKA (ss: *scilicet*)


COUNTRY OF JAPAN


On _____ 2010, before me, the undersigned, a Notary Public in and for said State, personally appeared TAKUMI KAWABE, personally known to me or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Signature of Notary Public

Official seal:




**EXHIBIT A**

<i>Country or Patent Office and Code</i>	<i>Application No. Effective Filing Date</i>	<i>Patent No. Issue Date</i>	<i>Title</i>	<i>PWSP Ref. No.</i>
Patents and patent applications with claiming priority to US Provisional Patent Application No. 60/350208 filed 1/17/2002				
United States of America US	60/350208 1/17/2002		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI-PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0282080
United States of America US	10/347145 1/17/2003	6995135 02/07/2006	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI-PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0301109
United States of America US	11/221348 09/06/2005	7476657 01/13/2009	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI-PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0317598
United States of America US	12/328632 12/04/2008		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI-PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0376203
World Intellectual Property Organization WO	PCT/IB03/000425 01/17/2003		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY THEIR USE	087533-0301110
Australia AU	2003235576 01/17/2003	2003235576 05/14/2009	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310231
Australia AU	2009201711 04/29/2009		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388408
Canada CA	2471192 01/17/2003		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310232
China CN	03806256.9 01/17/2003	ZL03806256.9 01/09/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310233
China CN	200710127024.3 06/15/2007		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0361436
Israel IL	162836 01/17/2003		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310235
Japan JP	2003-560044 01/17/2003	4041066 11/16/2007	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310236



<i>Country or Patent Office and Code</i>	<i>Application No. Effective Filing Date</i>	<i>Patent No. Issue Date</i>	<i>Title</i>	<i>PWSP Ref. No.</i>
Japan JP	2007-218979 08/24/2007		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388407
Republic of Korea KR	10-2004-7011092 01/17/2003	10-863090 10/06/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310237
Republic of Korea KR	10-2007-7031027 12/31/07		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388073
Norway NO	20043381 01/17/2003		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310238
South Africa ZA	2004/05455 01/17/2003	2004/05455 08/31/2005	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310239
European Patent Office EP	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0310234
Hong Kong HK	05102425.6 03/21/2005	HK1069179 05/22/2009	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0314296
Slovakia SK	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388474
Slovenia SI	P200331414 from EP 03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388476
Italy IT	73383/BE/2008 from EP 03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388477
Ireland IE	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388478
Greece GR	20080402751 from EP 03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388479
Germany DE	60322845.3 from EP 03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388480
Denmark DK	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388481




<i>Country or Patent Office and Code</i>	<i>Application No. Effective Filing Date</i>	<i>Patent No. Issue Date</i>	<i>Title</i>	<i>PWSP Ref. No.</i>
Lithuania LT	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388482
Switzerland CH	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388483
Cyprus CY	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388484
Czech Republic CZ	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388485
Hungary HU	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388487
Luxembourg LU	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388488
Bulgaria BG	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388489
Belgium BE	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388490
Albania AL	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388491
Macedonia MK	P-257/08 from EP 03729533.4 01/17/2003	903146 (EP1483290) 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388492
Turkey TR	03729533.4 01/17/2003	TR 2008 08284 T4 (EP1483290) 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388493
Austria AT	03729533.4 01/17/2003	E404584 (EP1483290) 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388495
United Kingdom GB	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388496




<i>Country or Patent Office and Code</i>	<i>Application No. Effective Filing Date</i>	<i>Patent No. Issue Date</i>	<i>Title</i>	<i>PWSP Ref. No.</i>
Congo CD	NP/08/EXT/09 filed 04/15/2009 based on EP1483290 08/13/2008		PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388497
Grenada GD	03729533.4 01/17/2003	EP1483290 Registered 04/28/2009	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388498
Latvia LV	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388499
Monaco MC	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388500
Estonia EE	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388501
Dominica DM	03729533.4 01/17/2003	Petition filed 04/30/2009	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388502
Spain ES	03729533.4 01/17/2003	ES2311703T3 (EP1483290) 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388561
Finland FI	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388562
France FR	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388563
Portugal PT	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388564
Sweden SE	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388565
Romania RO	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388566
Netherlands NL	03729533.4 01/17/2003	1483290 08/13/2008	PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI- PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS	087533-0388567





Country or Patent Office and Code	Application No. Effective Filing Date	Patent No. Issue Date	Title	PWSP Ref. No.
Patents and patent applications claiming priority to US Provisional Patent Application No. 60/461109 filed 04/07/2003				
United States of America US	60/461109 04/07/2003		ANTI-FUNGAL COMPOUNDS AND METHODS OF USE	087533-0302786
United States of America US	10/819375 04/05/2004	7,125,842 10/24/2006	ANTI-FUNGAL COMPOUNDS AND METHODS OF USE	087533-0306777
World Intellectual Property Organization WO	PCT/IB2004/001523 04/07/2004		ANTI-FUNGAL PEPTIDOMIMETICS	087533-0306778
Australia AU	2004228783 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317394
European Patent Office EP	04726239.9 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317396
Hong Kong HK	06104839.1 04/24/2006		ANTI-FUNGAL COMPOUNDS AND METHODS OF USE	087533-0325061
Canada CA	2521713 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317397
China CN	200480014915.2 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317398
Israel IL	171236 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317399
Japan JP	2006-506617 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317400
Korea KR	2005-7019170 04/07/2004		ANTI-FUNGAL PEPTIDOMIMETICS	087533-0317401
Norway NO	20055211 04/07/2004		ANTIFUNGALCOMPOUNDS AND METHODS OF USE	087533-0317402
South Africa ZA	2005/08094 04/07/2004	2005/08094 10/25/2006	ANTI-FUNGAL PEPTIDOMIMETICS	087533-0317403
Patents and patent applications claiming priority to US Provisional Patent Application No. 60/482750 filed 06/25/2003				
United States of America US	60/482750 06/25/2003		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0303824
United States of America US	10/877961 06/25/2004	7,479,484 01/20/2009	PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0309084
United States of America US	12/347683 12/31/2008		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0376959
World Intellectual Property Org. WO	PCT/IB2004/002591 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0309085



<i>Country or Patent Office and Code</i>	<i>Application No. Effective Filing Date</i>	<i>Patent No. Issue Date</i>	<i>Title</i>	<i>PWSP Ref. No.</i>
Australia AU	2004248998 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318661
Canada CA	2530900 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318662
China CN	200480018002.8 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318663
Israel IL	171801 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318664
Japan JP	2006-516613 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318665
Korea KR	2005-7024882 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318666
Norway NO	20060374 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318667
South Africa ZA	2005/10341 06/25/2004	2005/10341 03/20/2007	PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318668
European Patent Office EP	04744226.4 06/25/2004		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0318669
HK	06108620.5 03/08/06		PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	087533-0352299
Patents and patent applications claiming priority to US Provisional Patent Application Nos. 61/053190 filed 05/14/2008 and 61/116849 filed 11/21/2008				
United States of America US	61/053190 05/14/2008		PEPTIDE COMPOUND AND USE THEREOF	087533-0370489
United States of America US	61/116849 11/21/2008		PEPTIDE COMPOUND AND USE THEREOF	087533-0376102
United States of America US	12/465536 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388410



<i>Country or Patent Office and Code</i>	<i>Application No. Effective Filing Date</i>	<i>Patent No. Issue Date</i>	<i>Title</i>	<i>PWSP Ref. No.</i>
World Intellectual Property Org. WO	PCT/JP2009/059238 05/13/2009		CBP501 -DERIVED AGENTS AND METHODS BASED THEREON FOR INHIBITING G2 CELL CYCLE ARREST AND SENSITIZING CELLS TO DNA DAMAGING AGENTS	087533-0388409
Chile CL	1156-2009 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388074
Pakistan PK	411/2009 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388086
Venezuela VE	2009-000858 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388411
Bangladesh BD	(No serial no. received yet) 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388439
Taiwan TW	98115779 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388444
Lebanon LB	8613 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388445
Gulf Cooperation Council GC	13493 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388446
Uruguay UY	31,826 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388457
Jordan JO	176/2009 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388458
Peru PE	000669-2009/DIN 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388459
Thailand TH	0901002104 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388460
Argentina AR	P090101720 05/13/2009		PEPTIDE COMPOUND AND USE THEREOF	087533-0388461



平成22年登簿第 102 号

認 証

囑託人 河 邊 拓 己

は、本職の面前で、添付書面に署名した。


よって、これを認証する。

平成22年 11 月 5 日、本公証役場において

静岡県沼津市大手町三丁目6番18号
静岡地方法務局所属

公 証 人
Notary

江 幡 豊 秋
Toyoaki Ebata




総公証 No. H22 - 0505 号

証 明

この認証の付与は、在職中の公証人がその権限に基づいてしたものであり、かつ、その押印は、真実のものであることを証明する。

平成22年 11 月 5 日

静岡地方法務局長 石 井 末



C E R T I F I C A T E

This is to certify that the annexed Notarial Certificate has been executed by Notary, duly authorized and practising in Shizuoka, Japan, and that the Official Seal appearing on the same is genuine.

Date NOV. 5, 2010.

Suehiro Ishii

Director of the Shizuoka District Legal Affairs Bureau

PATENT

REEL: 025925 FRAME: 0341



Registered No. 102 of 2010

NOTARIAL CERTIFICATE

This is to certify that Takumi Kawabe has affixed his signature in my very presence to the attached document.

Dated this 5th day of November 2010

Toyoaki Ebata




Toyoaki Ebata

NOTARY

3-6-18 Ootemachi, Numazu-shi,

Shizuoka-Ken

Shizuoka District Legal Affairs Bureau



平成 22 年 登簿 第 5 4 2 号

認 証

囑託人 武田薬品工業株式会社 知的財産部長
奥村 洋一 は、当公証人の前でこの証書に署名した。

よって、これを認証する。

平成 22 年 11 月 29 日 当役場において

大阪市西区江戸堀一丁目 10 番 8 号

大阪法務局所属

公証人

見満正治



Registered No,542 of 2010


NOTARIAL CERTIFICATE

I, hereby certify that this document was signed before me and that the signature appearing on same is the true signature of Mr.Yoichi OKUMURA, General Manager, Intellectual Property Department of Takeda Pharmaceutical Company Limited.

Dated; on this 29th. day of November, 2010

Osaka Legal Affairs Bureau

Notary



Masaharu Kemma

Masaharu Kemma

10-8, Edobori 1-chome Nishi-ku,

Osaka, Japan.

大阪法務局所属 公証人役場

PATENT